{"id":7076,"date":"2025-08-18T12:34:07","date_gmt":"2025-08-18T12:34:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/7076\/"},"modified":"2025-08-18T12:34:07","modified_gmt":"2025-08-18T12:34:07","slug":"lipoprotein-levels-and-statin-treatment-related-to-dementia-and-cognitive-decline-in-individuals-with-type-2-diabetes-an-observational-analysis-from-the-advance-study-cardiovascular-diabetology","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/7076\/","title":{"rendered":"Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study | Cardiovascular Diabetology"},"content":{"rendered":"
  • \n

    Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pena JM, Selim MH, Woo D, American Heart Association Council on Arteriosclerosis T, Vascular B et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol 2023, 43<\/b>(10):e404\u201342<\/p>\n<\/li>\n

  • \n

    Crichton GE, Elias MF, Davey A, Sullivan KJ, Robbins MA. Higher HDL cholesterol is associated with better cognitive function: the Maine-Syracuse study. J Int Neuropsychol Soc. 2014;20(10):961\u201370.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u201317.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ying H, Wang J, Shen Z, Wang M, Zhou B. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35(1):153\u201366.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hua R, Ma Y, Li C, Zhong B, Xie W. Low levels of low-density lipoprotein cholesterol and cognitive decline. Sci Bull Beijing. 2021;66(16):1684\u201390.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Robinson JG. Low LDL-C levels: likely no short-term cognitive harm. J Am Coll Cardiol. 2020;75(18):2294\u20136.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Peters R, Xu Y, Antikainen R, Beckett N, Gussekloo J, Jagger C, Jukema JW, Keinanen-Kiukaanniemi S, Ryden L, Skoog I, et al. Evaluation of high cholesterol and risk of dementia and cognitive decline in older adults using individual patient meta-analysis. Dement Geriatr Cogn Disord. 2021;50(4):318\u201325.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis. 2017;56(1):215\u201328.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Gong J, Harris K, Peters SAE, Woodward M. Sex differences in the association between major cardiovascular risk factors in midlife and dementia: a cohort study using data from the UK Biobank. BMC Med. 2021;19(1):110.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lee YB, Kim MY, Han K, Kim B, Park J, Kim G, Hur KY, Kim JH, Jin SM. Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study. Sci Rep. 2022;12(1):19383.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    den Brok M, Eggink E, Hoevenaar-Blom MP, van Gool WA, Moll van Charante EP, Richard E, van Dalen JW. Low values for blood pressure, BMI, and non-HDL cholesterol and the risk of late-life dementia. Neurology. 2022;99(15):e1630\u20139.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Marcum ZA, Walker R, Bobb JF, Sin MK, Gray SL, Bowen JD, McCormick W, McCurry SM, Crane PK, Larson EB. Serum cholesterol and incident Alzheimer\u2019s disease: findings from the adult changes in thought study. J Am Geriatr Soc. 2018;66(12):2344\u201352.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tynkkynen J, Hernesniemi JA, Laatikainen T, Havulinna AS, Sundvall J, Leiviska J, Salo P, Salomaa V. Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer\u2019s disease: the national Finnish population study (FINRISK). Age (Dordr). 2016;38(5\u20136):465\u201373.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Svensson T, Sawada N, Mimura M, Nozaki S, Shikimoto R, Tsugane S. The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up. Transl Psychiatry. 2019;9(1):26.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kjeldsen EW, Thomassen JQ, Juul Rasmussen I, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R. Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. Cardiovasc Res. 2022;118(5):1330\u201343.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A et al. Low- and high-density lipoprotein cholesterol and dementia risk over 17 years of follow-up among members of a large health care plan. Neurology 2023.<\/p>\n<\/li>\n

  • \n

    Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D\u2019Agostino RB, Wolf PA. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med. 2003;163(9):1053\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Murray AM, Hsu FC, Williamson JD, Bryan RN, Gerstein HC, Sullivan MD, Miller ME, Leng I, Lovato LL, Launer LJ, et al. Accordion mind: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. 2017;60(1):69\u201380.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr, Waksman R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37(6):536\u201345.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324\u201333.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Pasini TS, Catapano AL, Mancia G. Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis. 2013;230(2):171\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chang CY, Lin FJ, Hong JL, Wu CH. Adherence to statins use and risk of dementia among patients with diabetes and comorbid hyperlipidemia. Inquiry. 2021;58:469580211019201.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Heymann AD, Ravona-Springer R, Moshier EL, Godbold J, Beeri MS. Statin use is associated with better cognitive function in elderly with type 2 diabetes. J Alzheimers Dis. 2015;47(1):55\u20139.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829\u201340.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Gong J, Harris K, Hackett M, Peters SAE, Brodaty H, Cooper M, Hamet P, Harrap S, Mancia G, MacMahon S, et al. Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: results from the ADVANCE trial. Diabetes Obes Metab. 2021;23(8):1775\u201385.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pikkemaat M, Woodward M, af Geijerstam P, Harrap S, Hamet P, Mancia G, Marre M, Poulter N, Chalmers J, Harris K. Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15935<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Woodward M, Patel A, Zoungas S, Liu L, Pan C, Poulter N, Januszewicz A, Tandon N, Joshi P, Heller S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 2011;34(12):2491\u20135.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484\u201393.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations\u2014Product Details for ANDA 075300 https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/results_product.cfm?Appl_Type=A&Appl_No=075300#25394<\/a><\/p>\n<\/li>\n

  • \n

    Wee J, Sukudom S, Bhat S, Marklund M, Peiris NJ, Hoyos CM, Patel S, Naismith SL, Dwivedi G, Misra A. The relationship between midlife dyslipidemia and lifetime incidence of dementia: a systematic review and meta-analysis of cohort studies. Alzheimers Dement (Amst). 2023;15(1): e12395.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Saeed A, Lopez O, Cohen A, Reis SE. Cardiovascular disease and Alzheimer\u2019s disease: the heart-brain axis. J Am Heart Assoc. 2023;12(21): e030780.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bruce DG, Davis WA, Davis TME. Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: the Fremantle diabetes study. J Diabetes Complications. 2017;31(6):945\u20137.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8): e005562.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cholesterol Treatment Trialists C, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, Hajebi A, Tschida S, Lemp JM, Aryal KK, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022;10(3):e369\u201379.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL, Casula M. Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804\u201314.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wang N, Harris K, Chalmers J, Harrap S, Mancia G, Marre M, Poulter N, Tzourio C, Williams B, Zoungas S, et al. Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE trials. J Hypertens. 2021;39(8):1689\u201396.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Liu MM, Peng J, Cao YX, Guo YL, Wu NQ, Zhu CG, Gao Y, Li JJ. The difference between fasting and non-fasting lipid measurements is not related to statin treatment. Ann Transl Med. 2021;9(5):386.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol. 2010;55(4):340\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343\u201354.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pena JM, Selim MH, Woo D, American Heart…\n","protected":false},"author":2,"featured_media":7077,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[7233,2908,7229,5195,868,2675,7230,18,135,19,17,7231,7232,6426],"class_list":{"0":"post-7076","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-angiology","9":"tag-cardiology","10":"tag-cholesterol","11":"tag-cognitive-decline","12":"tag-dementia","13":"tag-diabetes","14":"tag-diabetes-complications","15":"tag-eire","16":"tag-health","17":"tag-ie","18":"tag-ireland","19":"tag-lipids","20":"tag-lipoproteins","21":"tag-type-2-diabetes"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/7076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=7076"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/7076\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/7077"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=7076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=7076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=7076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}